Prognostic factors and survival outcomes in relapsed/refractory aggressive B‑cell lymphomas treated with epcoritamab. Blood Advances. 2026 Aug 25;10(16):5496-5504. DOI: 10.1182/bloodadvances.2026020171. PMID: 42263668. PMCID: PMC13486801.
The PubMed record lists a multi‑institutional authorship led by Allison M Bock and includes contributors from several major U.S. academic centers. Affiliations explicitly reported in the entry include the Division of Hematology/Hematologic Malignancies at the Huntsman Cancer Institute (University of Utah), the Department of Biostatistics and Lymphoma & Myeloma divisions at The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana‑Farber Cancer Institute, The Ohio State University College of Medicine, City of Hope, Vanderbilt University Medical Center, University of Colorado Anschutz School of Medicine, and the Fred & Pamela Buffett Cancer Center.
This PubMed entry provides standard bibliographic identifiers: PMID 42263668, DOI 10.1182/bloodadvances.2026020171, and PMCID PMC13486801. The record contains links to the journal site and to the free full text at PubMed Central. These links are the authoritative route to retrieve the complete manuscript, supplementary material, figures, and detailed methods and results.
The title indicates the manuscript examines prognostic factors and survival outcomes for patients with relapsed/refractory aggressive B‑cell lymphomas treated with the bispecific antibody epcoritamab. This places the study in the context of therapies for aggressive B‑cell non‑Hodgkin lymphomas that have failed prior lines of therapy. The focus on prognostic factors suggests the authors evaluated clinical or biological variables associated with outcomes after epcoritamab treatment; the term “survival outcomes” implies reporting of time‑to‑event endpoints such as overall survival (OS) and/or progression‑free survival (PFS).
The PubMed page provides full citation details, author names, institutional affiliations, and access links. It confirms journal, issue, page range, DOI, and open access status via PMC. The record also lists title and authors repeatedly across the page and indicates that the article appears in Blood Advances.
The excerpt of the PubMed page supplied here does not include the article abstract, methods, patient population size, inclusion/exclusion criteria, details of the epcoritamab dosing regimen, response rates, hazard ratios, median OS or PFS, statistical methods, subgroup analyses, safety or adverse event profiles, or conclusions drawn by the authors. Because these critical study elements are not present in the provided text, no study results, numeric outcomes, or specific prognostic factors can be summarized from this source alone.
If users require the study’s data — for example, which prognostic variables were significant, numeric survival estimates, or safety signals — those data must be obtained from the full text at the journal website or the PubMed Central record (PMCID PMC13486801).
The PubMed entry links to the journal landing page and to the free PMC article (PMCID PMC13486801). To obtain the full study details, readers should:
Note on content limitations
This rewritten summary is confined to information present in the provided PubMed page excerpt. Specific clinical results, numeric outcomes, and authors’ conclusions were not included in the supplied source text and therefore are not reported here. For application to clinical practice or research, consult the full published article and any related editorials or guidelines.